Accuray Helix receives CE Mark-Accuray’s new helical radiation delivery system

Accuray Incorporated announced the CE Mark approval for Accuray Helix, a CT-guided helical radiotherapy system designed for high performance and efficiency. Targeting emerging markets, where advanced cancer care is often limited to urban areas, the system addresses the gap in radiotherapy access. With fewer linear accelerators available than World Health Organization guidelines suggest, Accuray Helix offers a cost-effective, time-efficient solution for non-urban communities.

Radiotherapy is vital in cancer care, benefiting around 50% of patients, whether used alone or with surgery, chemotherapy, or immunotherapy. Accuray Helix provides precise, targeted radiation for routine cases like breast, cervix, lung, and prostate cancers. Its flexibility aims to personalize patient care, enhance clinic productivity, and meet growing demand.

Accuray is committed to advancing radiation therapy by creating innovative solutions that improve treatment for both complex and routine cancer cases, expanding access to life-saving care.